---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-024468"
form_type: "8-K"
ticker: "IRWD"
cik: "0001446847"
company_name: "IRONWOOD PHARMACEUTICALS INC"
filed_at: "2022-02-17T23:59:59+00:00"
generated_at: "2026-06-27T06:59:36.727388+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Ironwood Q4/FY2021: LINZESS blockbuster >$1B; total revenue $414M; pipeline advances

## Summary
- FY2021 total revenue $414M (driven by $400M LINZESS collab revenue); GAAP net income $528M (incl $338M tax benefit).
- Adjusted EBITDA $234M; year-end cash $620M.
- Non-GAAP diluted EPS $1.16 vs $0.79 in FY2020; Q4 Non-GAAP EPS $0.27.
- Initiated clinical studies for IW-3300 (visceral pain) and CNP-104 (primary biliary cholangitis).
- LINZESS U.S. net sales exceeded $1B in 2021, achieving blockbuster status.

## SEC filing metadata
- accession: 0001104659-22-024468
- form_type: 8-K
- ticker: IRWD
- cik: 0001446847
- company_name: IRONWOOD PHARMACEUTICALS INC
- filed_at: 2022-02-17T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1446847/000110465922024468/0001104659-22-024468-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1446847/000110465922024468/tm226866d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-024468
- JSON: https://secwatch.observer/filing/0001104659-22-024468.json
- Plain text: https://secwatch.observer/filing/0001104659-22-024468.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.